




Name	Nelli Bejanyan, M.D.	
Current Position	Associate Member, Program Leader of BMT, Head of Leukemia/Myeloid BMT-CI Section	
Country	USA	
Major Field	BMT and Cellular Immunotherapy	

Educational Background

Dr. Bejanyan obtained her Doctor of Medicine degree at the Yerevan State Medical University in Armenia. She subsequently completed her residency in Internal Medicine at Cleveland Clinic Ohio, followed by a year of fellowship in the Bone Marrow Failure and 3-year fellowship in Hematology/Oncology at the Taussig Cancer Institute at the Cleveland Clinic, USA.

Professional Experience

Dr. Bejanyan is an Associate Member, Program Leader of Blood and Marrow Transplant (BMT) and Head of the Leukemia/Myeloid Section of the BMT and Cellular Immunotherapy Department at Moffitt Cancer Center. She is an Associate Professor in Oncologic Sciences at the University of South Florida.

As a physician investigator with clinical and research expertise in BMT and cellular immunotherapies, Dr. Bejanyan focuses in advancing clinical and translational research by fostering innovative immune cell therapy strategies.

Dr. Bejanyan has been also actively involved as a primary investigator in several Center for International Blood and Marrow Transplant Research (CIBMTR) registry retrospective studies.

Other Experience and Professional Memberships

Dr. Bejanyan serves as the Co-chair of the Acute Leukemia Working Committee of the CIBMTR and as a member of the International Expert Panel for AML Relapse Committee, ASTCT MDS Expert Panel Committee, ASTCT Aplastic anemia Expert Panel Committee, BMT CTN Steering Committee, BMT CTN State of the Science Symposium Myeloid Malignancy Committee, and the CIBMTR Proposal Task Force.

Dr. Bejanyan has been an invited lecturer and chair at national and international conferences, and she served as a Coordinating Chair or Co-Chair of ASH and ASTCT annual meetings.

Main Scientific Publications



Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I, Aljurf M, Badawy SM, Beitinjaneh A, Boelens JJ, Diaz MA, Dvorak CC, Gadalla S, Gajewski J, Gale RP, Ganguly S, Gennery AR, George B, Gergis U, Gómez-Almaguer D, Vicent MG, Hashem H, Kamble RT, Kasow KA, Lazarus HM, Mathews V, Orchard PJ, Pulsipher M, Ringden O, Schultz K, Teira P, Woolfrey AE, Saldaña BD, Savani B, Winiarski J, Yared J, Weisdorf DJ, Antin JH, Eapen M. “Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia”. *Blood Adv.* 2019 Oct 22;3(20):3123-3131. doi: 10.1182/bloodadvances.2019000722. [PMID: 31648332](#)

Hansen DK, Kim J, Thompson Z, Hussaini M, Nishihori T, Ahmad A, Elmariah H, Faramand R, Mishra A, Davila ML, Khimani F, Lazaryan A, Sallman D, Liu H, Perez LE, Fernandez H, Nieder ML, Lancet JE, Pidala JA, Anasetti C, **Bejanyan N**. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. *Transplant Cell Ther.* 2021 Mar;27(3):256.e1-256.e7. doi: 10.1016/j.jtct.2020.12.021. Epub 2021 Feb 2. [PMID: 33781526](#)

Bejanyan, N., Zhang, M., Bo-Subait, K., Brunstein, C., Wang H, Warlick, E., Giral, S., Nishihori, T., Martino, R., Passweg, J., Dias, A., Copelan, E., Hale, G., Gale, R.P., Solh, M., Kharfani-Dabaja, M.A., Angel Diaz, M., Ganguly, S., Gore, S., Verdonck, L.F., Hossain, N.M., Kekre, N., Savani, B., Byrne, M., Kanakry, C., Cairo, M.S., Ciurea, S., Schouten, H., Bredeson, C., Munker, R., Lazarus, H., Cahn, J., van Der Poel, M., Rizzieri, D., Yared, J., Freytes, C., Cerny, J., Aljurf, M., Palmisiano, N., Pawarode, A., Bacher, V.U., Grunwald, M., Nathan, S., Wirk, B., Hildebrandt, G., Seo, S., Olsson, R.F., George, B., de Lima, M., Hourigan, C., Sandmaier, B., Litzow, M., Kebriaei, P., Saber, W., Weisdorf, D. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study. *Biol Blood Marrow Transplant.* 2020 Oct 1:S1083-8791(20)30618-2. doi: 10.1016/j.bbmt.2020.09.026. [PMID: 33010430](#)

Bejanyan, N., Brunstein, C.G., Cao, Q., Lazaryan, A., Ustun, C., Warlick, E.D., Arora, M., Wagner, J.E., Weisdorf, D. Predictive Value of Disease Risk Comorbidity Index for Overall Survival after Allogeneic Hematopoietic Transplantation. *Blood Adv.* 2019. Feb 12;3(3):230-236. doi: 10.1182/bloodadvances.2018018549. [PMID:30674457](#)

Bejanyan, N., Weisdorf, D.J., Logan, B.R., Wang, H.L., Devine, S.M., de Lima, M., Bunjes, D.W., Zhang, M.J. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. *Biol Blood Marrow Transplant.* 2015 Mar;21(3):454-9. PubMed PMID: [25460355](#); PubMed Central PMCID: [PMC4329076](#).

Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T, Locke FL, Perez Perez A, Dean E, Mishra A, Perez L, Lazaryan A, Jain MD, Nieder M, Liu H, Faramand R, Hansen D, Alsina M, Ochoa L, Davila M, Anasetti C, Pidala J, **Bejanyan N**. “Increased infections and delayed CD4+ T-cell but faster B-cell Immune Reconstitution after Posttransplant Cyclophosphamide Compared to Conventional GVHD prophylaxis in Allogeneic Transplantation” *Transplant Cell Ther.* 2021 Jul 27:S2666-6367(21)01105-2. doi: 10.1016/j.jtct.2021.07.023. PMID: 34329754

Otoukesh S, Elmariah H, Yang D, Clark MC, Siraj M, Ali H, Mogili K, Arslan S, Nishihori T, Nakamura R, Pidala J, Marcucci G, Forman SJ, Anasetti C, Al Malki MM, **Bejanyan N**. Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.



Transplant Cell Ther. 2021 Nov 26;S2666-6367(21)01397-X. doi: 10.1016/j.jtct.2021.11.012.

PMID: [34844022](#)

Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, Alsina M, Kharfan-Dabaja MA, Fernandez H, Nieder ML, Locke FL, Anasetti C, Ayala E. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. *Blood Adv.* 2021 Mar 9;5(5):1154-1163. doi: 10.1182/bloodadvances.2020003779. PMID: [33635333](#)

Bejanyan, N., Brunstein, C., Cao, Q., Lazaryan, A., Luo, X., Curtsinger, J., Mehta, R.S., Warlick, E., Cooley, S.A., Blazar, B.R., Miller, J.S., Weisdorf, D.J., Wagner, J.E., Verneris, M.R. Delayed Immune Reconstitution After Allogeneic Transplantation Increases the Risks of Mortality and Chronic GVHD. *Blood Adv.* 2018 Apr 24;2(8):909-922. doi: 10.1182/bloodadvances. PMID:[2017014464](#).

Bejanyan, N., Rogosheske, J., DeFor, T.E., Lazaryan, A., Arora, M., Holtan, S.G., Jacobson, P.A., MacMillan, M.L., Verneris, M.R., Blazar, B.R., Weisdorf, D.J., Wagner, J.E., Brunstein, C.G. Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft Versus Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. *Biol Blood Marrow Transplant.* 2016 Nov; 22(11):2025-2030. PMID: [27519278](#).

Complete List of Published Work in MyBibliography:

<https://www.ncbi.nlm.nih.gov/pubmed/?term=bejanyan+N>
